Guideline adherence in bone targeted treatment of cancer patients with bone metastases in Germany  Hartmut Link <sup>1</sup> Ingo Diel <sup>2</sup>
Carsten-H. Ohlmann <sup>3</sup> Laura Holtmann <sup>4</sup> Markus Kerkmann <sup>4</sup>
for the Associations Supportive Care in Oncology (AGSMO), Medical Oncology (AIO), Urological Oncology (AUO), within the German Cancer Society (DKG) and the German Osteooncological Society (DOG)
<sup>1</sup> Hämatologie, Onkologie, Pfaffplatz 10A, D- 67655 Kaiserslautern +49 631 14102, hlink@kabelmail.de
<sup>2</sup> Praxisklinik am Rosengarten, Augustaanlage 7-11, D-68165 Mannheim
<sup>3</sup> Malteser Krankenhaus Bonn/Rhein-Sieg, Von-Hompesch-Str.1, 53123 Bonn
<sup>4</sup> MMF GmbH, Heideblick 59, D-44229 Dortmund

all in Germany

Figure 3: Use of different bisphosphonates in lung, breast and prostate cancer. Pts with osteoprotective treatment




Figure 4A: systemic or radiotherapy, osteoprotective treatment and bone pain

\* Kruskal-Wallis-test

## all indications (n= 1766)

systemic or radiotherapy with osteoprotective treatment (n=1211) systemic or radiotherapy without osteoprotective treatment (n=374)

■ no systemic or radiotherapy, but osteoprotective treatment (n=91) • no systemic or radiotherapy, no osteoprotective treatment (n=90)




Figure 4B: systemic or radiotherapy, osteoprotective treatment and bone pain

\* Kruskal-Wallis-test lung cancer (n= 414) ■ systemic or radiotherapy with osteoprotective treatment (n=180) **■** systemic or radiotherapy without osteoprotective treatment (n=155) ■ no systemic or radiotherapy, but osteoprotective treatment (n=27) ■ no systemic or radiotherapy, no osteoprotective treatment (n=52) p < 0.001\*70% 60% 50% 44% 38% 40% 35% 33% 29% 29% 30% 26% 19% 17% 14% 20% 15% 13% 15% 10% 8% 7% 10% 0% 0% unknown / Lost to follow up of bone pain (n=93) worsening of Improvement unchanged bone paln (n=63) bone paln (n=77) painless /

Figure 4C: systemic or radiotherapy, osteoprotective treatment and bone pain

\* Kruskal-Wallis-test

## breast cancer (n= 803)

■ systemic or radiotherapy with osteoprotective treatment (n=675) systemic or radiotherapy without osteoprotective treatment (n=81)




Figure 4D: systemic or radiotherapy, osteoprotective treatment and bone pain

\* Kruskal-Wallis-test

## prostate cancer (n= 549)

systemic or radiotherapy with osteoprotective treatment (n=356) systemic or radiotherapy without osteoprotective treatment (n=138)

■ no systemic or radiotherapy, but osteoprotective treatment (n=40) • no systemic or radiotherapy, no osteoprotective treatment (n=15)

